CoChat

Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases

Open access

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Background: Since the warnings by the United States (US) and European regulatory authorities in 2004 and 2005 it had been discussed whether there is some link between selective serotonin reuptake inhibitors (SSRIs) and suicidality in the pediatric population. The aim of our study was to describe trends and patterns in spontaneous reporting data referring to suicidality in children, adolescents and young adults treated with SSRI after the warnings. Methods: Descriptive analyses of reports for 0–24 year olds referring to suicide/suicidal ideations, self-harms and overdoses with SSRIs reported as suspected submitted to the US (FAERS) and the European (EudraVigilance) adverse drug reaction databases until 2019 were performed. The causal relationship was assessed in accordance with the WHO criteria for the European reports. For Germany, prescription data for SSRIs were provided and reporting rates (number of reports/number of prescriptions) were calculated for the reports with possible causal relationship (so called “confirmed reports”). Results: Since 2004, the number of reports referring to suicide/suicidal ideations, self-harm and overdoses increased steadily in the US and EU. However, only a slight increase was seen for the confirmed EU reports. After 2008, the proportion of reports informing about suicidal ideations increased, while the proportion of fatal suicide attempts decreased. Reporting rates were higher for females and adolescents (12-18 years). Conclusions: Our results demonstrate the importance of further monitoring suicidality in 0–24 year olds treated with SSRI in order to recognize suicidality early avoiding fatal suicide attempts. The higher reporting rates for females and adolescents should be further investigated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40360-023-00664-z

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart. Research strategy for identification of intentional suicide/suicidal behaviour and overdose reports referring to selective serotonin reuptake inhibitors (SSRIs) in the European ADR database EudraVigilance and the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). ADR: Adverse drug reaction; EEA: European Economic Area
Fig. 1 Flowchart. Research strategy for identification of intentional suicide/suicidal behaviour and overdose reports referring to selective serotonin reuptake inhibitors (SSRIs) in the European ADR database EudraVigilance and the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). ADR: Adverse drug reaction; EEA: European Economic AreaCC BY · PubMed Central
Fig. 2 Annual number of reports from EudraVigilance and FAERS referring to intentional suicide/suicidal behaviour or overdose associated with SSRI. Legend to Fig. 2: EEA: European Economic Area; Confirmed EEA reports: reports from the European economic area with a possible causal relationship of suicidality related to SSRI treatment following causality assessment applying WHO criteria [20]. US: United States of America, FAERS: Food and Drug Administration (FDA) Adverse Event Reporting System
Fig. 2 Annual number of reports from EudraVigilance and FAERS referring to intentional suicide/suicidal behaviour or overdose associated with SSRI. Legend to Fig. 2: EEA: European Economic Area; Confirmed EEA reports: reports from the European economic area with a possible causal relationship of suicidality related to SSRI treatment following causality assessment applying WHO criteria [20]. US: United States of America, FAERS: Food and Drug Administration (FDA) Adverse Event Reporting SystemCC BY · PubMed Central
Fig. 3 Annual number of confirmed selective serotonin reuptake inhibitor (SSRI) reports from Germany divided by sex and age groups
Fig. 3 Annual number of confirmed selective serotonin reuptake inhibitor (SSRI) reports from Germany divided by sex and age groupsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 22

Metadata

Authors
Dubrall, D., Fekete, S., Leitzen, S., Paschke, L. M., Romanos, M., Schmid, M., Gerlach, M., & Sachs, B.
Affiliations
  • Federal Institute for Drugs and Medical Devices (DE)
  • Universitätsklinikum Würzburg (DE)
  • University Hospital Bonn (DE)
Corresponding author
Fekete, Stefanie
Venue
BMC Pharmacology and Toxicology
Published
2023-03-31
Volume
24
Issue
1
Pages
22-22
ISSN
2050-6511 (ISSN-L)
OpenAlex
W4362523560
Cited by
15
References
43
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 5
FWCI
4.36
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Pharmacology and Toxicology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Funders
  • Federal Institute for Drugs and Medical Devices
  • Institute for Medical Biometry, Informatics, and Epidemiology
  • University Hospital of Bonn
  • German innovation fund of the Federal Joint Committee (01NVF16021)
  • Universitätsklinikum Würzburg
Topics
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
selective serotonin reuptake inhibitors, suicidality, adverse drug reactions, suicide attempts, suicidal ideation, self-harm, drug overdose, pharmacovigilance, reporting rates, adolescents, sex differences
MeSH terms
Adolescent, Child, Female, Humans, Suicide, Suicide, Attempted, United States, Selective Serotonin Reuptake Inhibitors, Young Adult, Suicidal Ideation, Pharmacovigilance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases. https://app.cochat.ai/papers/10.1186/s40360-023-00664-z
The paper
Dubrall, D., Fekete, S., Leitzen, S., Paschke, L. M., Romanos, M., Schmid, M., Gerlach, M., & Sachs, B. (2023). Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-023-00664-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.